Janux Therapeutics (NASDAQ:JANX) Shares Cross Above 50 Day Moving Average – Here’s What Happened

Posted by Brian Himes on Oct 30th, 2026

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $17.59 and traded as high as $18.07. Janux Therapeutics shares last traded at $18.05, with a volume of 984,134 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on JANX shares. Guggenheim lowered their price target on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Friday, August 7th. TD Cowen upgraded Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wolfe Research raised Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a research note on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Friday, October 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Janux Therapeutics in a research report on Monday, October 19th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Janux Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $36.46.

View Our Latest Research Report on Janux Therapeutics

Janux Therapeutics Stock Performance

The firm has a fifty day simple moving average of $17.60 and a 200-day simple moving average of $15.32. The company has a market capitalization of $1.07 billion, a PE ratio of -10.65 and a beta of 2.40.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.10). The firm had revenue of $10.27 million during the quarter, compared to the consensus estimate of $19.07 million. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.70 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in shares of Janux Therapeutics by 67.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after purchasing an additional 661 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after purchasing an additional 784 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Janux Therapeutics in the third quarter worth about $54,000. Quantbot Technologies LP grew its stake in Janux Therapeutics by 2,290.0% in the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock worth $84,000 after purchasing an additional 5,267 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Janux Therapeutics in the second quarter worth about $174,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.